All data are based on the daily closing price as of September 1, 2025
p

PharmaEngine

4162.TWO
2.15 USD
-0.05
-2.27%

Overview

Last close
2.15 usd
Market cap
304.97M usd
52 week high
3.68 usd
52 week low
2.15 usd
Target price
3.92 usd

Valuation

P/E
5.8959
Forward P/E
N/A
Price/Sales
3.8144
Price/Book Value
2.0438
Enterprise Value
134.71M usd
EV/Revenue
1.6619
EV/EBITDA
1.9894

Key financials

Revenue TTM
81.06M usd
Gross Profit TTM
79.48M usd
EBITDA TTM
66.34M usd
Earnings per Share
0.37 usd
Dividend
0.2 usd
Total assets
195.59M usd
Net debt
N/A usd

About

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
  • Symbol
    4162.TWO
  • Exchange
    TWO
  • Isin
    TW0004162003
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Hong-Ren Wang Ph.D.
  • Headquarter
    Taipei
  • Web site
    https://www.pharmaengine.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top